Home |  Contact Us | Site Map

Investor Relations

Corporate Profile

Welcome! Whether you are a potential investor in BioCryst Pharmaceuticals or you are already a shareholder, our investor center is the primary source of information about the company. Just choose a topic, or if you have a question, e-mail us.

NASDAQ: BCRX
$4.82 + 0.11
Sep 27, 2016 at 11:24 AM ET
Intraday data provided by eSignal

Recent Releases View All Releases

BioCryst Closes $23 Million Senior Credit Facility 
Cash runway extended to early 2018; Facility to be repaid with RAPIVAB revenues  RESEARCH TRIANGLE PARK, N.C., Sept. 26, 2016 (GLOBE NEWSWIRE) --  BioCryst Pharmaceuticals, ...

Read More

BioCryst Announces Positive Study Results for BCX4430 Delayed Treatment of Ebola Virus Infection in a Non-Human Primate Model
RESEARCH TRIANGLE PARK, N.C., Sept. 07, 2016 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced positive results from a proof-of-concept study of it...

Read More

Investor Relations

Rob Bennett, Vice President Investor Relations & Operations
919.859.7910
investorrelations@biocryst.com

Proxy Online

For more information click here.

Stockholder Services

Questions about stock transfers and lost certificates should be directed to the transfer agent:
American Stock Transfer & Trust Company
59 Maiden Lane
New York, NY 10038
1-800-937-5449 (toll free in US and Canada)
1-718-921-8200 (callers outside the US and Canada)